ICU
SeaStar Medical·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
High Gross Profit Margin
Low Cash Short-term Debt Ratio
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ICU
Seastar Medical Holding Corp
A medical technology company developing innovative solutions for critically ill patients, including extracorporeal therapies
Healthcare Equipment and Supplies
06/06/2007
03/18/2021
NASDAQ Stock Exchange
19
12-31
Common stock
3513 Brighton Blvd, Suite 410, Denver, CO 80216
--
SeaStar Medical Holding Corp was originally incorporated in Delaware on June 6, 2007 under the name Nephrion, Inc. On August 3, 2007, the company changed its name to CytoPherx Corporation. On June 19, 2019, in a merger transaction, CytoPherx changed its name to SeaStar Medical, a medical technology company focused on the development and commercialization of its lead product candidate, the Selective Cellular Heterotrophic Device (" SCD "), for acute kidney injury (" AKI ") indications in children and adults. SeaStar Medical is currently completing a submission for a Humanitarian Equipment Exemption (" HDE ") for SCD for the treatment of pediatric AKI patients with continuous renal replacement therapy (" CRRT ") and completing the design of a pivotal trial for adult AKI patients with CRRT. SCD received Breakthrough Device Designation from the U.S. Food and Drug Administration (" FDA ") on April 29, 2022 for the treatment of immune modulation disorders in adults aged 18 years and older with AKI.
Earnings Call
Q2/2025
Estimate EPS--
Actual EPS-0.18
Estimate Revenue200.00K
Actual Revenue338.00K
SeaStar Medical's Q2 2025: Unpacking Contradictions in Quellimmune Launch and Pediatric Market Growth
Aug 14,2025 05:41
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ICU has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.15, beating expectations. The chart below visualizes how ICU has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ICU has released its 2025 Q3 earnings report, with revenue of 183.00K, reflecting a YoY change of 169.12%, and net profit of -3.47M, showing a YoY change of 22.47%. The Sankey diagram below clearly presents ICU's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
